Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
about
Current and emerging treatment options in the management of lupusManagement of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future PerspectivesBelimumab in systemic lupus erythematosusCytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus ErythematosusB-cell survival factors in autoimmune rheumatic disordersCellular targeting in autoimmunityUpdate on pathogenesis and treatment of CLEProfile of atacicept and its potential in the treatment of systemic lupus erythematosusDrugs derived from phage display: from candidate identification to clinical practiceNeuropsychiatric lupus: a mosaic of clinical presentationsPediatric lupus nephritis: Management updateDrugs for discoid lupus erythematosus.Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity.Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned.Novel treatments for immune thrombocytopenia.Haematological manifestations of lupus.Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical studyOptimal management of fatigue in patients with systemic lupus erythematosus: a systematic review.Efficacy and safety data of belimumab in patients with systemic lupus erythematosus.A rare case of prototheca algaemia in a patient with systemic lupus erythematosus and recent belimumab infusion.A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.Belimumab for the treatment of systemic lupus erythematosus.Neuropsychiatric Symptoms in LupusClinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.Immunosuppressive Medications.Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3.B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.Cytokine disturbances in systemic lupus erythematosus.The Diagnosis and Treatment of Systemic Lupus ErythematosusEfficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year.Diagnosis and risk stratification in patients with anti-RNP autoimmunity.Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicineInhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).Genetics of Lupus Nephritis: Clinical Implications.B Cells, Antibodies, and More.Belimumab in systemic lupus erythematosus: an update for clinicians.A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients.Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis.Latest advances in connective tissue disorders.
P2860
Q26741266-7176CCD5-4417-4C1E-BB9E-ED72E45605C0Q26774815-EDEC5C0F-0E46-42DA-B663-040EB63B0B58Q26778277-96126416-48C6-42BE-B889-C80846AC13DBQ26782454-F13245AA-09A1-44D3-B299-C8FD2BE67903Q26796484-EA3F0C0B-45FB-4882-957C-C35F6B8E0A1EQ26824580-6F068B8F-6335-4A5A-BDE3-2BE526117CF7Q26827054-6A86AD92-6D2F-480A-9137-AF160786E6FAQ26849719-A3FE37B8-A55F-402E-82B0-AA4E219347A8Q27007101-3507B59A-A018-4427-B5FC-A9A005469CA8Q27027588-A6BF9121-67B6-483E-A64C-8E39EDB9F7F1Q28660110-5F1D343A-6550-4746-9E23-AAF32DEF13D8Q30234556-8F61E685-31F7-4C93-9476-FAFF1F1CD742Q30415556-3AD357CE-5565-4010-BB7F-CAB3CA656816Q31160251-BCB3021E-A8D4-4D55-8D30-9C6F686871D7Q33414132-B5E704A2-3AA1-4225-8E97-33C432A39DB7Q33421876-6D522B3D-2E4F-4F8E-A75B-9D13C38DD859Q33767123-25E16702-8132-46AD-869E-C4CF5C2466EAQ34351248-BBAD8DB2-50FC-4500-ADEA-6B2298085A40Q34369628-3841780A-3F23-4C13-8A5F-87251969D523Q34394509-B452A958-533B-4A59-B09D-88209C3D4EE7Q34416115-5B7BCE5E-BD3F-43C8-81D5-5189C6F3D5ACQ34455827-CE90E1E5-BB74-406A-BE0A-56F0FBFBC80AQ34459628-6263F3FF-4495-4878-BE4E-CAB027ACEAA6Q34478853-DEE59D0F-5222-47BA-BBE8-B9537F62795FQ34484801-5AB1F0A9-0B2E-496D-A4F5-3A8FA64D3DBCQ34667834-D9D3A484-A704-418E-819D-D7B6CA4D8772Q34781487-9D9C6A37-16B0-43BB-A23A-733F51F00A7CQ35617573-B556B4F2-A3AA-4991-B1C1-6B0890441FFBQ35692998-7B1043E7-F48D-45FA-BC16-2F8D5B8242EBQ35761089-5C0FB5CA-963E-4320-B05E-F769F762582AQ35768902-30C1117E-ECF7-45DA-BAB2-49E488284048Q35930490-5B6464F1-B453-47CA-A1A4-733BDE5C7152Q36088877-484DEA5D-39DD-4096-ABE9-5BC7898593A9Q36271212-F0D4D4A9-6F40-4316-B195-E2F976BF9E80Q36300008-E941453C-DF4E-465E-99DE-CABBCDD2A4FCQ36432935-527E6155-12F8-4170-BED8-497419402481Q36443781-C8AA3E36-F5B6-437B-BC26-01D1A264F8E5Q36549197-7063CB3B-6B77-4E06-A64E-F9095BBDF46BQ37030677-B8CB1631-E392-4AD4-9152-72BBC95FD7D1Q37058776-739ECAB9-BB67-4DEA-BA5F-C7443242A2BC
P2860
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Effects of belimumab, a B lymp ...... ults from two phase III trials
@ast
Effects of belimumab, a B lymp ...... ults from two phase III trials
@en
type
label
Effects of belimumab, a B lymp ...... ults from two phase III trials
@ast
Effects of belimumab, a B lymp ...... ults from two phase III trials
@en
prefLabel
Effects of belimumab, a B lymp ...... ults from two phase III trials
@ast
Effects of belimumab, a B lymp ...... ults from two phase III trials
@en
P2093
P2860
P50
P1476
Effects of belimumab, a B lymp ...... ults from two phase III trials
@en
P2093
BLISS-52 and BLISS-76 Study Groups
David P D'Cruz
Ellen M Ginzler
Joan T Merrill
Jorge Sánchez-Guerrero
Richard Furie
Sandra V Navarra
Simon Cooper
Susan Manzi
William Freimuth
P2860
P304
P356
10.1136/ANNRHEUMDIS-2011-200831
P407
P577
2012-05-01T00:00:00Z